Therapy Areas: Vaccines
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
26 November 2025 - Vaccine company Valneva SE (Nasdaq:VALN) (Euronext Paris:VLA) on Wednesday reported positive final Phase 2 immunogenicity and safety results for its Lyme disease vaccine candidate, ...
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
26 November 2025 - AI-powered drug discovery and biodefence company Lunai Bioworks (NASDAQ:LNAI) announced on Tuesday that it has received its first Letter of Intent (LOI) to license its next-generati...
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
19 November 2025 - BioNet, a biotechnology company developing and manufacturing next generation vaccines including recombinant and mRNA vaccines, announced on Tuesday that it has received positive opi...
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
12 November 2025 - Biotechnology company Anixa Biosciences Inc (NASDAQ: ANIX) announced on Wednesday that the United States Patent and Trademark Office will issue U.S. Patent No. 12,472,205 on 18 Nove...
ExpreS2ion Biotech signs definitive licensing deal with Serum Institute of India for novel malaria vaccines
12 November 2025 - Danish clinical-stage biotechnology company ExpreS2ion Biotechnologies ApS, an affiliate of ExpreS2ion Biotech Holding AB (STO: EXPRS2), announced on Wednesday that it has signed a ...
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
7 November 2025 - PharmaJet®, a leader in needle-free drug delivery systems designed to improve outcomes and patient comfort, has confirmed a new Distribution Agreement with ATR, an affiliate comp...